Primary goal of this non-interventional study is to evaluate the change in level of allergen-specific IgE (EAST class) after allergen-specific immunotherapy with Pollinex Quattro with tree and/or grass pollen extracts and their mixtures under medial routine at adults with tree- and/or grass-medicated pollinosis.
In this non-interventional study, the change in level of allergen-specific IgE before and after 3 or more years of allergen-specific immunotherapy with Pollinex Quattro in a patient population with tree and/or grass pollen induced pollinosis and/or asthma will be analyzed. In addition, the change in medication usage, asthma status for asthmatic patients after 3, 4 or 5 years of allergen specific immunotherapy will be evaluated. Furthermore, patients will be asked for their change in quality of life after therapy end.
Study Type
OBSERVATIONAL
Enrollment
113
retrospective analysis of patient records of allergen-specific immunotherapy
Outpatient Center Dr Stollewerk/Niebecker
Cologne, Germany
Change in allergen specific IgE after allergen-specific immunotherapy
Efficacy
Time frame: baseline, post-treatment (after at least 3 years of allergen-specific immunotherapy)
Change in medication usage after allergen-specific immunotherapy
Efficacy
Time frame: baseline, post-treatment (after at least 3 years of allergen-specific immunotherapy)
Change in FEV1 (forced expiratory volume at one second; measured in %) after allergen-specific immunotherapy
Efficacy
Time frame: baseline, post-treatment (after at least 3 years of allergen-specific immunotherapy)
Change in lung function resistance (measured in Kpa/l/s) after allergen-specific immunotherapy
Efficacy
Time frame: baseline, post-treatment (after at least 3 years of allergen-specific immunotherapy)
Assessment of allergic eye symptoms (itching, tearing, redness, feeling of pressure) , on a scale 0 -10 (none - severe) after allergen-specific immunotherapy
Efficacy
Time frame: baseline, post-treatment, at least 3 years of allergen-specific immunotherapy
Assessment of allergic nasal symptoms (rhinorrhea, nasal obstruction) , on a scale 0 -10 (none - severe) after allergen-specific immunotherapy
Efficacy
Time frame: baseline, post-treatment, at least 3 years of allergen-specific immunotherapy
Assessment of allergic lung/bronchial symptoms (shortness of breath, cough), on a scale 0 -10 (none - severe) after allergen-specific immunotherapy
Efficacy
Time frame: baseline, post-treatment, at least 3 years of allergen-specific immunotherapy
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.